Cercar
01/09/2024
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
Puig, L, Costanzo, A, de Jong, EMGJ, Torres, T, Warren, RB, Wapenaar, R, Wegner, S, Gorecki, P, Gramiccia, T, Jazra, M, Buyze, J, Conrad, C. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial. Dermatology and Therapy. 2024; 14(9)DOI:10.1007/s13555-024-01245-6. PMID:39153060. IF:4.200(Q1/1D).
01/09/2024
A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study
Puig, L, Belloso, RI, Rivera-Díaz, R, Sánchez, JM, Fernández-Freire, LR, Sahuquillo-Torralba, A, Ruiz-Villaverde, R. A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study. DERMATOLOGY. 2024; 240(5-6)DOI:10.1159/000540019. PMID:39019021. IF:2.700(Q2/4D).
01/09/2024
Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease
Puig, L, Tsai, TF, Soriano, ER, Bhutani, T, Miller, M, Kollmeier, AP, Li, S, You, Y, Petrick, M, Li, HW, Patel, H, Lavie, F, Gooderham, M, Londo o, A, Lebwohl, M, Nash, P. Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
Tha i, D, Puig, L, Merola, JF, Jullien, D, Costanzo, A, Wang, M, Deherder, D, Pinto, JML, Lebwohl, M. Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions
Ständer, S, Pereira, MP, Zeidler, C, Legat, FJ, Misery, L, Loenndahl, L, Bewley, AP, Brenaut, E, Bobko, S, Elberling, J, Evers, AWM, Garcovich, S, Gieler, U, Goncalo, M, Kupfer, J, Lambert, J, Lvov, A, Metz, M, Michenko, A, Papadavid, E, Reich, A, Savk, E, Schneider, G, Schut, C, Serra-Baldrich, E, Ständer, HF, Szepietowski, JC, Wallengren, J, Weisshaar, E, Augustin, M. EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2024; 38(9)DOI:10.1111/jdv.20102. PMID:38738586. IF:8.000(Q1/1D).
08/08/2024
Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis
Silverberg, JI, Bieber, T, Paller, A, Beck, LA, Kamata, M, Puig, L, Wiseman, M, Ezzedine, K, Foley, P, Johansson, E, Dossenbach, M, Akmaz, B, Casillas, M, Karlsson, A, Chovatiya, R. Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis. BRITISH JOURNAL OF DERMATOLOGY. 2024; 191DOI:10.1093/bjd/ljae266.014. PMID:. IF:9.600(Q1/1D).
03/08/2024
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, trials
Bissonnette, R, Warren, RB, Pinter, A, Agner, T, Gooderham, M, Schuttelaar, MLA, Crépy, MN, Stingeni, L, Serra-Baldrich, E, Baranowski, K, Korn, S, Kurvits, M, Plohberger, U, Vest, NS, Schliemann, S. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, trials. LANCET. 2024; 404(10451)DOI:10.1016/S0140-6736(24)01027-4. PMID:39033766. IF:88.500(Q1/1D).
01/08/2024
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search
Puig, L, Fujita, H, Thaçi, D, Zheng, M, Daly, ACH, Leonardi, C, Lebwohl, MG, Barker, J. Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search. Dermatology and Therapy. 2024; 14(9)DOI:10.1007/s13555-024-01230-z. PMID:39088126. IF:4.200(Q1/1D).